Phospho-GRIA1 (S849) Antibody

What is GRIA1 and why is its phosphorylation at S849 important?

GRIA1, also known as GluA1 or GluR1, is a subunit of the AMPA receptor that plays a crucial role in excitatory neurotransmission in the central nervous system. Phosphorylation of GRIA1 at various sites, including S849, regulates the trafficking and functional properties of AMPA receptors, directly impacting synaptic strength and plasticity . This post-translational modification is particularly important for investigating mechanisms underlying synaptic transmission and the pathophysiology of neurological disorders such as Alzheimer's disease and epilepsy . The phosphorylation status at S849 provides valuable insights into how neurons modulate their excitability and synaptic connections during normal function and disease states.

How does Phospho-GRIA1 (S849) Antibody differ from antibodies targeting other phosphorylation sites?

The Phospho-GRIA1 (S849) Antibody (CABP0242) is specifically designed to recognize GRIA1 when phosphorylated at serine 849, distinguishing it from antibodies targeting other phosphorylation sites such as S831, S836, T840, or S845 . Each phospho-specific antibody targets a unique epitope surrounding its respective phosphorylation site. For example, the immunogen for Phospho-GRIA1 (S849) Antibody is "a phospho-specific peptide corresponding to residues surrounding S849 of human GluR1/GRIA1" , while the S836 antibody targets a different region. These distinct phosphorylation sites mediate different cellular responses and signaling pathways, allowing researchers to investigate specific aspects of GRIA1 regulation. Research suggests that different phosphorylation sites may be activated under varying physiological conditions and may have distinct impacts on AMPA receptor function .

What are the main experimental applications for Phospho-GRIA1 (S849) Antibody?

The Phospho-GRIA1 (S849) Antibody has been validated primarily for Western blot and ELISA applications . In Western blot analysis, the recommended dilution range is 1:500 to 1:2000 . This antibody is particularly valuable for:

• Detecting and quantifying phosphorylated GRIA1 in various cell types and tissues, especially in brain samples

• Studying changes in GRIA1 phosphorylation during synaptic plasticity

• Investigating GRIA1 phosphorylation in neurological disorder models

• Monitoring alterations in AMPA receptor regulation in response to pharmacological treatments

• Examining the role of GRIA1 phosphorylation in learning and memory processes

The antibody has been specifically tested with rat brain as a positive sample , making it particularly suitable for neuroscience research focused on synaptic transmission and plasticity mechanisms.

What is the specificity and reactivity profile of the Phospho-GRIA1 (S849) Antibody?

The Phospho-GRIA1 (S849) Rabbit Polyclonal Antibody (CABP0242) demonstrates reactivity against human, mouse, and rat samples . The antibody is of IgG isotype and is supplied in an unconjugated format . It has been specifically designed to recognize GRIA1 only when phosphorylated at the S849 position, enabling researchers to distinguish between phosphorylated and non-phosphorylated forms of the protein. The high specificity is achieved through the use of a phospho-specific peptide immunogen corresponding to residues surrounding S849 of human GluR1/GRIA1 . This specificity allows researchers to accurately detect changes in the phosphorylation state of GRIA1 without cross-reactivity with other phosphorylation sites or unphosphorylated protein, though validation with appropriate controls is always recommended for each experimental setup.

How can I accurately quantify the stoichiometry of GRIA1 phosphorylation at S849?

Quantifying the stoichiometry of GRIA1 phosphorylation requires specialized techniques due to the relatively low proportion of phosphorylated receptor in physiological conditions. Based on studies with other GRIA1 phosphorylation sites (S831 and S845), the basal level of phosphorylation may be quite low—less than 1% for S831 and less than 0.1% for S845 . For accurate quantification of S849 phosphorylation, consider these approaches:

• Phos-tag SDS-PAGE: This technique separates phosphorylated from non-phosphorylated proteins based on mobility shifts, allowing direct visualization and quantification of phosphorylation stoichiometry. Research has validated that this method provides results consistent with mass spectrometric absolute quantification (AQUA) .

• Western blotting with phospho-specific antibodies: Use both the Phospho-GRIA1 (S849) antibody and a total GRIA1 antibody on parallel samples to calculate the ratio of phosphorylated to total protein.

• Mass spectrometry: For absolute quantification, consider AQUA methodology using synthetic standard phosphorylated and unphosphorylated peptides labeled with 13C and 15N .

When analyzing results, be aware that even with stimulation, the proportion of phosphorylated GRIA1 may remain relatively low, requiring sensitive detection methods and careful interpretation .

What are the optimal sample preparation protocols for detecting Phospho-GRIA1 (S849) in brain tissue?

For optimal detection of Phospho-GRIA1 (S849) in brain tissue samples, follow these methodological steps:

• Tissue collection and preservation:

  • Rapidly dissect and flash-freeze brain tissue in liquid nitrogen to preserve phosphorylation status

  • Alternatively, use phosphatase inhibitors immediately during dissection

• Protein extraction:

  • Homogenize tissue in ice-cold lysis buffer containing comprehensive phosphatase inhibitor cocktails

  • Include 1% SDS or other strong detergents to solubilize membrane proteins like GRIA1

  • Maintain cold temperatures throughout processing to prevent dephosphorylation

• Sample preparation for Western blot:

  • For standard SDS-PAGE: Denature samples at 70°C instead of boiling to prevent potential dephosphorylation

  • For Phos-tag SDS-PAGE: Follow specific protocols that enable separation of phosphorylated proteins

• Controls:

  • Include phosphatase-treated samples as negative controls

  • Consider using brain tissue from knockout models or after pharmacological manipulation as reference points

The recommended positive control is rat brain tissue , and the suggested working dilution for Western blot is 1:500 to 1:2000 . Given that GRIA1 is localized to cell junctions, cell membrane, dendrites, dendritic spines, and postsynaptic membranes , subcellular fractionation protocols may be employed to enrich for these compartments when analyzing specific cellular populations.

How can I investigate the relationship between multiple phosphorylation sites on GRIA1?

Investigating the interplay between multiple GRIA1 phosphorylation sites (such as S831, S836, T840, S845, and S849) requires specialized approaches to detect single and dual phosphorylation events:

• Phos-tag SDS-PAGE combined with phospho-specific antibodies:

  • This technique can separate singly and dually phosphorylated forms of GRIA1

  • Sequential blotting with different phospho-specific antibodies allows identification of each phosphoisotype

  • Research has demonstrated that this approach can detect GluA1 dually phosphorylated at S831 and S845, which migrates at a position similar to singly phosphorylated GluA1 at T840

• Mutational analysis:

  • Generate mutants with selective phosphorylation sites available (e.g., maintain S849 and one other site while mutating others to alanine)

  • This approach helps analyze how different combinations of phosphorylation affect protein function

• Temporal analysis:

  • Monitor changes in different phosphorylation sites following various stimuli

  • This reveals whether sites are phosphorylated sequentially or simultaneously

• Pharmacological manipulation:

  • Use specific kinase and phosphatase inhibitors to selectively modulate individual phosphorylation sites

  • This helps determine functional relationships and hierarchies between sites

Research suggests that dual phosphorylation of GRIA1 may be rare under basal conditions but can increase with neuronal stimulation or learning . Understanding these relationships is crucial as different phosphorylation patterns may encode distinct functional outcomes for AMPA receptor trafficking and activity.

What neurological disorder models are most relevant for studying GRIA1 S849 phosphorylation?

GRIA1 has been implicated in several neurological disorders, making the study of its phosphorylation at S849 particularly relevant in these research models:

• Neurodevelopmental disorders (NDDs):

  • GRIA1 has been established as a human NDD-causing gene

  • Models studying GRIA1 missense and truncating variants can provide insights into developmental pathologies

• Alzheimer's disease models:

  • GRIA1 phosphorylation is implicated in synaptic dysfunction in Alzheimer's disease

  • Transgenic mouse models exhibiting amyloid pathology may show altered GRIA1 phosphorylation patterns

• Epilepsy models:

  • As GRIA1 phosphorylation affects excitatory neurotransmission, it is relevant in studying seizure disorders

  • Models of temporal lobe epilepsy may reveal changes in GRIA1 S849 phosphorylation

• Depression and stress models:

  • Phosphoproteomics approaches have been used to investigate stress-induced depression and the antidepressant effects of ketamine

  • GRIA1 phosphorylation may be altered in chronic stress paradigms and following antidepressant treatment

• Learning and memory models:

  • Evidence suggests that learning increases GRIA1 phosphorylation, albeit the proportion remains relatively low

  • Behavioral training paradigms coupled with phosphorylation analysis can reveal functional correlations

For each model, comparing basal phosphorylation levels with those after experimental manipulation provides valuable insights into the role of S849 phosphorylation in disease pathophysiology and potential therapeutic interventions.

Why might I be unable to detect Phospho-GRIA1 (S849) in my samples despite detecting total GRIA1?

Detection difficulties for phosphorylated GRIA1 at S849 may occur for several methodological reasons:

• Low stoichiometry of phosphorylation:

  • Research on other GRIA1 phosphorylation sites (S831 and S845) has shown extremely low basal phosphorylation levels—less than 1% for S831 and less than 0.1% for S845

  • S849 may similarly have very low basal phosphorylation, requiring enrichment or highly sensitive detection methods

• Rapid dephosphorylation during sample processing:

  • Phosphatases remain active during sample collection and preparation unless adequately inhibited

  • Implement a comprehensive phosphatase inhibitor strategy including:

    • Multiple phosphatase inhibitor types (serine/threonine and tyrosine phosphatase inhibitors)

    • Sodium fluoride (50 mM), sodium orthovanadate (1 mM), and β-glycerophosphate (10 mM)

    • Immediate sample processing at cold temperatures

• Antibody sensitivity limitations:

  • The recommended dilution range (1:500 - 1:2000) may need optimization for your specific samples

  • Consider signal amplification methods or more sensitive detection systems

• Detection method inadequacy:

  • Standard Western blotting may be insufficient for very low phosphorylation levels

  • Consider using Phos-tag SDS-PAGE which has been demonstrated to detect even small amounts of phosphorylated GRIA1

• Sample-specific factors:

  • Verify that your experimental conditions would indeed lead to S849 phosphorylation

  • Consider using positive controls known to increase GRIA1 phosphorylation (e.g., treatment with okadaic acid as demonstrated for other phosphorylation sites)

How can I improve signal-to-noise ratio when detecting Phospho-GRIA1 (S849)?

Optimizing signal-to-noise ratio for Phospho-GRIA1 (S849) detection requires attention to several methodological factors:

• Sample enrichment strategies:

  • Immunoprecipitate total GRIA1 before probing for phosphorylated forms

  • Perform subcellular fractionation to enrich for membrane proteins where GRIA1 is primarily located

  • Consider phosphoprotein enrichment techniques using metal affinity chromatography

• Blocking optimization:

  • Use 5% BSA in TBS-Tween 20 for blocking (rather than milk, which contains phosphoproteins)

  • Extend blocking time to 2 hours at room temperature to reduce non-specific binding

• Antibody incubation parameters:

  • Optimize primary antibody dilution through titration experiments

  • Extend primary antibody incubation to overnight at 4°C

  • Use carrier proteins like BSA in antibody diluent

• Detection system selection:

  • Employ enhanced chemiluminescence (ECL) with extended exposure times

  • Consider fluorescent secondary antibodies and imaging systems for greater linear range

  • Quantify using digital imaging systems rather than film for better sensitivity

• Membrane handling:

  • Use nitrocellulose membranes which may provide better signal-to-noise ratio for phosphoproteins

  • Optimize transfer conditions to ensure complete protein transfer

• Technical controls:

  • Include phosphatase-treated samples as negative controls

  • Use rat brain tissue as a positive control as recommended

By systematically optimizing these parameters, researchers can significantly improve detection sensitivity and specificity for the relatively low-abundance phosphorylated form of GRIA1 at S849.

What are the critical parameters for reproducing Western blot results with Phospho-GRIA1 (S849) Antibody?

Reproducible Western blot results with Phospho-GRIA1 (S849) Antibody require strict control of several critical parameters:

• Sample handling consistency:

  • Maintain identical sample collection protocols across experiments

  • Ensure consistent phosphatase inhibitor cocktail implementation

  • Standardize protein extraction buffers and procedures

  • Process all samples within the same timeframe to prevent variable dephosphorylation

• Protein quantification and loading:

  • Perform accurate protein quantification using methods unaffected by detergents

  • Load equal amounts of protein (validate with housekeeping protein controls)

  • Consider using GAPDH (1:1,000 dilution) as a loading control

• Electrophoresis conditions:

  • For standard SDS-PAGE: Maintain consistent polyacrylamide percentage

  • For Phos-tag SDS-PAGE: Strictly control Phos-tag reagent concentration and running conditions

  • Maintain consistent voltage and running time

• Transfer efficiency:

  • Standardize transfer conditions (time, amperage, buffer composition)

  • Verify transfer efficiency with reversible staining before blocking

• Antibody parameters:

  • Use antibodies from the same lot when possible

  • Maintain consistent dilutions (1:500 - 1:2000 as recommended)

  • Standardize incubation times and temperatures

  • Use HRP-conjugated Goat Anti-Rabbit IgG at 1:2,000 dilution for detection

• Signal detection standardization:

  • Use identical exposure times between experiments

  • Employ the same detection reagents and imaging equipment

  • Quantify band intensities using standardized analysis software and protocols

• Controls implementation:

  • Include phosphatase-treated negative controls

  • Use rat brain as a positive control

  • Consider including calibration standards for quantitative comparisons

By controlling these parameters, researchers can achieve consistent and reproducible results when detecting the phosphorylated form of GRIA1 at S849.

How should I interpret changes in GRIA1 S849 phosphorylation in the context of synaptic plasticity?

Interpreting changes in GRIA1 S849 phosphorylation requires careful consideration of several factors:

• Baseline phosphorylation levels:

  • Research on other GRIA1 phosphorylation sites indicates extremely low basal phosphorylation (less than 1% for S831 and less than 0.1% for S845)

  • Even small absolute changes may represent significant relative increases

• Temporal dynamics:

  • Consider both immediate (minutes) and sustained (hours) changes in phosphorylation

  • Rapid, transient phosphorylation may indicate immediate synaptic responses

  • Persistent phosphorylation may suggest longer-term synaptic modifications

• Synaptic vs. extrasynaptic pools:

  • Distinguish between changes in synaptic GRIA1 (localized to postsynaptic densities) versus extrasynaptic receptors

  • Subcellular localization information indicates GRIA1 can be found in cell junctions, cell membrane, dendrites, and dendritic spines

• Relationship to other phosphorylation sites:

  • Consider potential interactions with other phosphorylation sites (S831, S845, etc.)

  • Determine whether dual phosphorylation occurs after stimulation

• Functional correlates:

  • Correlate phosphorylation changes with electrophysiological measurements (AMPA receptor currents)

  • Connect phosphorylation events to behavioral or cognitive outcomes in intact animals

• Statistical considerations:

  • Due to low stoichiometry, larger sample sizes may be needed for reliable detection of changes

  • Use appropriate statistical tests that account for the typically non-normal distribution of phosphorylation data

Remember that neuronal stimulation and learning can increase GRIA1 phosphorylation, though the proportion typically remains relatively low . Changes should be interpreted in the context of the specific experimental paradigm and correlated with functional outcomes where possible.

How do phosphorylation patterns at S849 compare with other known GRIA1 phosphorylation sites?

Understanding how S849 phosphorylation relates to other GRIA1 phosphorylation sites provides important context for interpreting experimental results:

• Stoichiometric differences:

  • Research indicates extremely low basal phosphorylation at S831 (<1%) and S845 (<0.1%)

  • S849 phosphorylation levels may similarly be very low under basal conditions

  • T840 appears to have higher basal phosphorylation (~5%) compared to other sites

• Regulation by different kinases:

  • Different phosphorylation sites are targeted by distinct kinases:

    • S831: CaMKII and PKC

    • S845: PKA

    • S849: May have unique kinase regulators that should be determined experimentally

• Functional distinctions:

  • S831 phosphorylation increases single-channel conductance

  • S845 phosphorylation increases open probability and promotes surface expression

  • S849 phosphorylation effects should be compared with these established functions

• Co-occurrence patterns:

  • Research has detected GluA1 dually phosphorylated at S831 and S845, but this appears rare under basal conditions

  • Whether S849 can be co-phosphorylated with other sites requires investigation using Phos-tag SDS-PAGE combined with phospho-specific antibodies

• Response to stimuli:

  • Different phosphorylation sites may respond differently to various stimuli:

    • Neuronal activity

    • Learning paradigms

    • Pharmacological agents

    • Pathological conditions

• Temporal dynamics:

  • Some sites may show rapid and transient phosphorylation

  • Others may exhibit delayed but sustained phosphorylation

  • Comparing these patterns across sites provides insight into sequential regulation

Understanding these comparative aspects helps interpret S849 phosphorylation in the broader context of GRIA1 regulation and AMPA receptor function in normal physiology and disease states.

What are the implications of GRIA1 S849 phosphorylation for neurodevelopmental disorders?

The role of GRIA1 S849 phosphorylation in neurodevelopmental disorders (NDDs) should be considered in light of several key findings:

• GRIA1 as an NDD-causing gene:

  • Research has established GRIA1 as a human NDD-causing gene that merits inclusion in the collection of GRIA-related NDDs

  • Missense and truncating variants of GRIA1 have been identified and functionally evaluated in relation to neurodevelopmental disorders

• Potential mechanistic contributions:

  • Altered S849 phosphorylation may affect:

    • AMPA receptor trafficking to synapses during critical developmental periods

    • Synaptic strength and plasticity during circuit formation

    • Excitatory/inhibitory balance in developing neural networks

• Relationships with other GRIA1 domains:

  • Consider how S849 phosphorylation might interact with:

    • Disease-causing mutations in other regions of GRIA1

    • Other post-translational modifications

    • Protein-protein interactions critical for development

• Therapeutic implications:

  • Understanding S849 phosphorylation may reveal:

    • Novel drug targets for NDDs

    • Biomarkers for disease progression or treatment response

    • Personalized therapeutic approaches based on specific GRIA1 variants

• Developmental timing considerations:

  • S849 phosphorylation may have age-dependent effects:

    • Critical periods during brain development

    • Different consequences in developing versus mature circuits

    • Potential for age-specific therapeutic interventions

• Model system relevance:

  • When studying S849 phosphorylation in NDD models, consider:

    • How well the model recapitulates human GRIA1 regulation

    • Developmental trajectories of different model organisms

    • Translation of findings between in vitro and in vivo systems

Given GRIA1's established role in NDDs , investigating S849 phosphorylation may provide valuable insights into molecular mechanisms and potential therapeutic approaches for these disorders.

How can phosphoproteomics approaches complement antibody-based detection of GRIA1 S849 phosphorylation?

Phosphoproteomics offers several advantages that complement traditional antibody-based detection of GRIA1 S849 phosphorylation:

• Unbiased discovery of phosphorylation sites:

  • Mass spectrometry-based phosphoproteomics can identify novel or unexpected phosphorylation sites on GRIA1

  • This approach has been successfully applied in investigating mechanisms underlying stress-induced depression and ketamine's antidepressant effects

• Absolute quantification capabilities:

  • Mass spectrometry absolute quantification (AQUA) provides precise stoichiometry measurements

  • This approach uses synthetic standard phosphorylated and unphosphorylated peptides labeled with 13C and 15N

  • When compared with Phos-tag SDS-PAGE for S831 phosphorylation quantification, AQUA results coincided precisely with the gel-based method

• Simultaneous analysis of multiple modifications:

  • Phosphoproteomics can detect multiple phosphorylation sites simultaneously

  • This enables identification of phosphorylation patterns that may have functional significance

  • The technique can reveal relationships between different phosphorylation sites that may not be apparent with site-specific antibodies

• Network-level insights:

  • Phosphoproteomics provides a broader view of signaling networks

  • This helps place GRIA1 S849 phosphorylation in the context of other signaling events

  • Such analysis can reveal upstream regulators and downstream effectors

• Lower dependence on antibody quality:

  • Phosphoproteomics is not limited by antibody specificity issues

  • This is particularly valuable when antibodies show cross-reactivity or insufficient sensitivity

• Integration with other -omics approaches:

  • Phosphoproteomics data can be integrated with transcriptomics, proteomics, and metabolomics

  • This multi-omics approach provides a more comprehensive understanding of GRIA1 regulation

A combined approach using both phospho-specific antibodies and phosphoproteomics offers the most comprehensive analysis strategy, leveraging the strengths of each method while compensating for their respective limitations.

What are the emerging technologies that might improve detection and functional analysis of GRIA1 S849 phosphorylation?

Several cutting-edge technologies are poised to advance our understanding of GRIA1 S849 phosphorylation:

• Single-molecule imaging techniques:

  • Super-resolution microscopy can visualize individual AMPA receptors and their phosphorylation states

  • These approaches overcome the limitation that most synapses may not contain any phosphorylated AMPAR due to low stoichiometry

  • Live-cell imaging with phospho-sensors can track real-time changes in phosphorylation

• CRISPR-based approaches:

  • CRISPR/Cas9 gene editing enables:

    • Generation of phospho-mimetic or phospho-deficient mutations

    • Knock-in of fluorescent tags for visualization

    • Precise study of S849 phosphorylation effects on receptor function

  • Single guide RNA (sgRNA) design principles demonstrated in neurogenetic studies can be applied

• Proximity labeling proteomics:

  • BioID or APEX2 fusion proteins can identify proteins interacting with phosphorylated GRIA1

  • This helps map signaling networks specific to the phosphorylated state

• Optogenetic and chemogenetic tools:

  • Light or drug-inducible kinases and phosphatases targeting GRIA1

  • Allows temporal control of phosphorylation with unprecedented precision

  • Enables causal testing of phosphorylation effects on synaptic function

• Cryo-electron microscopy:

  • Near-atomic resolution structures of phosphorylated versus non-phosphorylated AMPA receptors

  • Insights into conformational changes induced by phosphorylation

• Single-cell phosphoproteomics:

  • Analysis of phosphorylation heterogeneity across individual neurons

  • Correlation with electrophysiological properties of the same cells

• Computational modeling:

  • Molecular dynamics simulations of phosphorylation effects on receptor structure and function

  • Network models integrating phosphorylation data with other signaling pathways

These technologies promise to overcome current limitations in studying low-abundance phosphorylation events and provide unprecedented insights into the functional significance of GRIA1 S849 phosphorylation in health and disease.

How should researchers integrate GRIA1 phosphorylation data with other experimental approaches in neuroscience?

Effective integration of GRIA1 phosphorylation data with other neuroscience approaches requires a multidisciplinary strategy:

• Electrophysiological correlation:

  • Pair phosphorylation analysis with patch-clamp recordings to link molecular changes to functional outcomes

  • Measure AMPA receptor-mediated currents before and after manipulations that alter S849 phosphorylation

  • Correlate phosphorylation stoichiometry with synaptic strength measurements

• Behavioral paradigms:

  • Connect phosphorylation changes to learning and memory processes

  • Research indicates learning can increase phosphorylation of GRIA1, though proportions remain relatively low

  • Design experiments that capture phosphorylation states at behaviorally relevant timepoints

• Circuit-level analysis:

  • Combine phosphorylation studies with circuit mapping techniques

  • Determine if S849 phosphorylation varies across different neural circuits

  • Identify circuit-specific consequences of altered phosphorylation

• Disease model integration:

  • Study S849 phosphorylation in models of neurodevelopmental disorders where GRIA1 has been implicated

  • Investigate phosphorylation changes in models of neurological conditions like Alzheimer's disease and epilepsy

  • Use phosphorylation data to inform therapeutic strategies

• Developmental trajectory analysis:

  • Map changes in S849 phosphorylation across developmental stages

  • Correlate with critical periods for synaptic plasticity

  • Investigate developmental disorders associated with GRIA1 dysfunction

• Multi-omics integration:

  • Combine phosphoproteomics with transcriptomics and proteomics

  • Similar approaches have been used to investigate stress-induced depression and ketamine's antidepressant effects

  • Build comprehensive models of GRIA1 regulation across multiple molecular levels

• Computational neuroscience:

  • Develop mathematical models incorporating phosphorylation data

  • Simulate effects of phosphorylation on neural network function

  • Predict system-level consequences of altered GRIA1 phosphorylation